Saniona AB (publ) (STO:SANION)

Market Cap	1.42B -15.3%
Revenue (ttm)	424.56M +25.0%
Net Income	183.53M -14.4%
EPS	1.31 -28.3%
Shares Out	138.03M
PE Ratio	6.91
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	413,868
Open	9.35
Previous Close	9.03
Day's Range	9.35 - 10.34
52-Week Range	8.53 - 28.30
Beta	1.16
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 44
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 13, 2026

Data Sources Report a data error